DermTech, a biotechnology company developing skin sampling technologies for early disease detection, has appointed John Quackenbush to the company’s scientific advisory board.
Quackenbush is a professor of biostatistics and computational biology at the Dana-Farber Cancer Institute and professor of computational biology and bioinformatics at the Harvard School of Public Health.
Quackenbush was the 1992 recipient of a five-year fellowship from the National Center for Human Genome Research to study various aspects of genomics, Quackenbush and has done considerable work in the areas of biological data management, analysis, and interpretation.
NextBio has appointed B. Michael Silber, former senior vice president and site head of preclinical R&D (Safety & Technical Sciences) at Roche Pharmaceuticals, to its company's Scientific Advisory Board.
Compendia Bioscience has announced that co-founder Dan Rhodes will serve as the principal investigator on the company’s National Cancer Institute-funded, $2.4 million “fast track” project entitled “Development of Oncomine Professional as a Platform for Biopharmaceutical Research and Development.”
In so doing, he will assume a full time position at Compendia Bioscience as its CEO
John Freshley,will transition from CEO to the company’s chief business officer, overseeing sales, marketing and corporate development.